6315-S (FLOMOXEF) IN OBSTETRICS AND GYNECOLOGY
スポンサーリンク
概要
- 論文の詳細を見る
Pharmacological and clinical studies of 6315-S (flomoxef) were performed, and the following results obtained.<BR>1. Average peak concentration in exudate of pelvic dead space was 27.0μg/ml at 3h after i. v. infusion of 1g, which thereafter gradually decreased.<BR>2. Mean concentration after i. v. infusion was 6.0μg/ml in venous serum, 7.2μg/ml in uterine arterial serum, 2.6μg/g in endometrium, 4.3μg/g in myometrium, 4.4μg/g in the cervix, 4.5μg/g in the portio vaginalis, 4.5μg/g in the ovary and 4.7μg/g in the oviduct.<BR>3. 6315-S was administered to 4 patients with genital infection for 3-4 days at a dose of 1 g b. i. d. Clinical effects were excellent in 1 patients, good in 2 and poor in 1 patient.<BR>4. No side effects or adverse effects in clinical laboratory findings were observed.
- 公益社団法人 日本化学療法学会の論文
公益社団法人 日本化学療法学会 | 論文
- DISPOSITION OF 7432-8 IN RATS (I)
- CLINICAL STUDIES ON T-1220 IN SURGICAL CASES
- CLINICAL STUDIES OF PIVALOYLOXYMETHYL D-α-AMINOBENZYL-PENICILLINATE HYDROCHLORIDE IN SURGICAL INFECTIONS
- STUDIES ON AC-1370
- Primary treatment with a combination of cyclophosphamide, vincristine, and dacarbazine for recurrent malignant pheochromocytoma: A case report.